Price
$0.5339
Increased by 0.00%
Dollar Volume
22.80 K
ADR%
10.48
Earnings Report Date (estimate)
Mar 27, 23 (-0.73)
Market Cap.
7.91 M
Shares Float
6.90 M
Shares Outstanding
14.82 M
Beta
1.99
Price / Earnings
-0.20
BPR
2.12
20D Range
0.36 0.59
50D Range
0.36 0.68
200D Range
0.36 3.91
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 4, 22 -0.66
Increased by 0.00%
-0.49
Decreased by -34.69%
Nov 3, 22 -0.66
Increased by +2.94%
-0.49
Decreased by -34.69%
Aug 15, 22 -0.54
Increased by +28.00%
-0.65
Increased by +16.92%
May 16, 22 -0.66
Increased by +12.00%
-0.68
Increased by +2.94%
Mar 28, 22 -0.66
Increased by +10.81%
-0.61
Decreased by -8.20%
Nov 15, 21 -0.68
Increased by +6.85%
-0.80
Increased by +15.00%
Aug 13, 21 -0.75
Decreased by -2.74%
-0.63
Decreased by -19.05%
Aug 12, 21 -0.75
Decreased by -27.12%
-0.63
Decreased by -19.05%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 91.00 K
Decreased by -85.44%
-10.19 M
Decreased by -4.00%
Decreased by -11.20 K%
Decreased by -614.30%
Jun 30, 22 38.00 K
Decreased by -95.01%
-156.00 K
Increased by +98.56%
Decreased by -410.53%
Increased by +71.18%
Mar 31, 22 458.00 K
Decreased by -52.98%
-10.03 M
Decreased by -4.80%
Decreased by -2.19 K%
Decreased by -122.87%
Dec 31, 21 0.00
Decreased by -100.00%
-10.05 M
Decreased by -6.93%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 625.00 K
Decreased by -5.02%
-9.80 M
Decreased by -31.70%
Decreased by -1.57 K%
Decreased by -38.66%
Jun 30, 21 761.00 K
Decreased by -27.18%
-10.84 M
Decreased by -61.52%
Decreased by -1.42 K%
Decreased by -121.79%
Mar 31, 21 974.00 K
Decreased by -2.70%
-9.57 M
Decreased by -45.01%
Decreased by -982.34%
Decreased by -49.03%
Dec 31, 20 1.00 M
Increased by +169.89%
-9.40 M
Decreased by -73.30%
Decreased by -936.06%
Increased by +35.79%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.